# US 2024/0067937 A1 · Microorganism for producing human milk oligosaccharide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0067937 A1
- Document ID: US20240067937A1
- Status: Published application
- Kind: A1
- Application number: 18/497,736
- Filed: 2023-10-30
- Published: 2024-02-29
- Earliest claimed: 2017-08-01
- Assignees: OligoScience Biotechnology GmbH
- Applicants: OligoScience Biotechnology GmbH
- Inventors: Max Peracha; Sabrina Wernhoff; Friedhelm Meinhardt
- Web page: https://patentgrep.com/patent/US20240067937A1

## CPC

- C07K 14/245: Escherichia (G)
- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- A23K 20/163: Sugars; Polysaccharides
- A23L 33/00: Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- C07K 14/435: from animals; from humans
- C12N 1/20: Bacteria; Culture media therefor
- C12P 19/18: produced by the action of a glycosyl transferase, e.g. alpha-, beta- or gamma-cyclodextrins
- C12Y 204/0104: Glycoprotein-fucosylgalactoside alpha-N-acetylgalactosaminyltransferase (2.4.1.40)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Human milk oligosaccharides (HMOs) may be used e.g. as functional ingredients in infant nutrition, medical nutrition, functional foods and animal feed. There is still a need of improved means of producing HMOs. The present invention provides genetically modified microorganisms for the improved production of HMOs and HMO production methods using the same. The microorganisms of the invention may have one or more yield-enhancing modifications, including an inducible lysis system, which allows for the easy extraction of intracellular and extracellular HMOs, lactose permease mutants, which may increase intracellular lactose levels, or chaperones, which may increase intracellular availability of key enzymes for the production of HMOs.

## Claims

### Claim 1

A genetically modified microorganism for the production of human milk oligosaccharide, wherein the microorganism is optionally a bacterium, and preferably Escherichia coli (E. coli).

### Claim 2 (depends on 1)

The genetically modified microorganism according to claim 1, wherein the microorganism comprises an inducible lysis system, wherein the inducible lysis system is optionally auto-inducible.

### Claim 3 (depends on 2)

The genetically modified microorganism according to claim 2, wherein the inducible lysis system is Mg2+-regulated, and/or wherein the inducible lysis system is optionally regulated by the exogenous free Mg2+ concentration, and/or wherein the microorganism optionally comprises a Mg2+-regulated promoter, and/or wherein the microorganism further optionally comprises an additional Mg2+-regulated element, preferably the 5′UTR of the mgtA gene of Escherichia coli.

### Claim 4 (depends on 2, 3)

The genetically modified microorganism according to any one of claims 2 to 3, wherein the microorganism comprises a lysis genes, wherein the lysis gene is optionally a lysis gene from a bacteriophage.

### Claim 5 (depends on 2, 3, 4)

The genetically modified microorganism according to any one of claims 2 to 4, wherein the microorganism comprises a Mg2+-regulated promoter and lysis genes, wherein expression of the lysis gene(s) is controlled by the Mg2+-regulated promoter, and optionally by an additional Mg2+-regulated element.

### Claim 6 (depends on 1, 2, 3, 4, 5, 6, 7)

The genetically modified microorganism according any one of claims 1 to 7, wherein the microorganism is unable to cleave lactose into glucose and galactose, and/or wherein optionally the lac operon is inactivated, preferably by deletion.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The genetically modified microorganism according to any one of claims 1 to 6, wherein the microorganism comprises an exogenous gene encoding a lactose permease, wherein the lactose permease is preferably the E. coli LacY protein, wherein the lactose permease optionally has A198V and/or S209I mutations.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The genetically modified microorganism according to any one of claims 1 to 7, wherein the human milk oligosaccharide is 2′-Fucosyllactose and/or 3′-Fucosyllactose.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The genetically modified microorganism according to any one of claims 1 to 8, wherein the microorganism comprises an exogenous gene encoding a fucosyltransferase, wherein the fucosyltransferase is preferably an α-1,2-fucosyltransferase and/or an α-1,3-fucosyltransferase, wherein the gene encoding a fucosyltransferase is optionally a heterologous gene and/or wherein the gene encoding a fucosyltransferase is optionally driven by a heterologous promoter, wherein optionally the gene encoding a fucosyltransferase is codon-optimized for expression in the microorganism.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The genetically modified microorganism according to any one of claims 1 to 9, wherein the microorganism comprises a heterologous gene encoding a chaperone, wherein the chaperone is preferably human Hsp70.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The genetically modified microorganism according to any one of claims 1 to 8, wherein optionally the rcsA gene, preferably derived from E. coli, is overexpressed; and/or optionally a gene encoding a Lon protease family protein, preferably E. coli Lon protease, is inactivated, preferably by deletion; and/or optionally the wcaJ gene is inactivated, preferably by deletion; and/or optionally the zwf gene and the two pntAB genes, preferably derived from E. coli, are overexpressed; and/or optionally the gsk gene, preferably derived from E. coli, is overexpressed; and/or optionally the trxA gene, preferably derived from E. coli, is overexpressed; and/or optionally the trxB gene is inactivated, preferably by deletion.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method for producing human milk oligosaccharide, which comprises:
(a) culturing the genetically modified microorganism according to any one of claims 1 to 11 in a medium, wherein the medium further optionally comprises lactose and/or free Mg2+, wherein optionally the concentration of the human milk oligosaccharide in the medium at the end of the culture is at least 30 g/L, preferably at least 50 g/L, wherein preferably the human milk oligosaccharide is 2′-Fucosyllactose and/or 3′-Fucosyllactose.

### Claim 13 (depends on 12)

The method for producing human milk oligosaccharide according to claim 12, which further comprises:
(b) purifying the human milk oligosaccharide from the culture medium and/or from the microorganism itself, wherein optionally the human milk oligosaccharide is purified from the culture medium after lysis has been induced via the inducible lysis system, and/or wherein optionally the human milk oligosaccharide is purified from the culture medium when the concentration of free Mg2+ in the medium is 10 μM or less and/or when the lysis can be directly visualized.

### Claim 14 (depends on 12, 13)

Medium obtainable by the method according to claim 12 or human milk oligosaccharide obtainable by the method according to claim 13.

### Claim 15 (depends on 14)

Use of the medium or of the human milk oligosaccharide according to claim 14 for the preparation of animal feed.
